Voltar
Carta Acesso aberto Revisado por pares
BIBTEX RIS

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

2018; Ferrata Storti Foundation; Volume: 103; Issue: 9 Linguagem: Inglês

10.3324/haematol.2018.187617

ISSN

1592-8721

Autores

Paolo Strati, Dai Chihara, Yasuhiro Oki, Luis Fayad, Nathan Fowler, Loretta J. Nastoupil, Jorge Romaguera, Felipe Samaniego, Naveen Garg, Lei Feng, Emily Wesson, Charnelle Ruben, Mildred D. Stafford, Yago Nieto, Issa F. Khouri, Chitra Hosing, Sandra B. Horowitz, Rammurti T. Kamble, Michelle A. Fanale,

Tópico(s)

CAR-T cell therapy research

Resumo

The survival outcome of patients with peripheral T-cell lymphoma (PTCL) who experience relapse or progression following first-line treatment is generally very poor.[1][1] It can improve for patients who are able to receive stem cell transplantation (SCT), particularly if remission prior to

Referência(s)